Anwaar Saeed

🙏🏻 @NatureComms for being the 🏡 to our foundational work 😇✨✨ 🙏🏻 my fearless team of investigators for the Elite teamwork ⛷️⛷️⛷️ >>>> watch out for our follow up paper with deeper molecular dive & AI work 😎 nature.com/articles/s4146…

😇 Honored to serve as discussant for #ASCO25 oral upper GI abstracts. A powerhouse session with science featured simultaneously in 2 @NEJM papers, 1 @TheLancet , and 1 @JCO_ASCO —field-leading science shaping our GI oncology practice ✨. @UPMCHillmanCC

New in Cancer: Joint series w/ @AnnSurgOncol on consensus guidelines for managing peritoneal surface malignancies from a multidisciplinary expert panel. 🎥 Watch an intro from @kturaga and explore the full collection: acsjournals.onlinelibrary.wiley.com/doi/toc/10.100… @OncoAlert @YaleMedicine

For dMMR colon cancer, FOLFOX + atezolizumab per ATOMIC is now incorporated into the NCCN Guidelines. @MayoCancerCare @ALLIANCE_org @ASCOPost @CCAlliance @RueschCenter @FightCRC

Amazing work by @OsamaYo81168721 and the team. Happy to have been a senior author on this and thanks to @AnwaarSaeed3 for the opportunity! Through this bioinformatic approach we have shown the protective role of ENHO in PAAD. Learn more on: doi.org/10.3390/cancer…

I already discussed this news with some of my patients… just showing what an important area of unmet need you have addressed! God bless you :)

Congratulations, Dr. Saeed! What a journey that started from CAMILLA! Looking forward to seeing the full results ✨

So happy for my mentor @AnwaarSaeed3 You rock! 🧬 🌟

Congrats Anwaar. Huge Slay!! Practice changing!!! @OncoAlert @ASCO @DavendraSohal

Congratulations @AnwaarSaeed3 on your pioneering work! 👏🏽👏🏽👏🏽 I remember how exciting it was to hear you talk about the responses you were seeing on your CAMILLA trial. Can’t wait to 👀 the new data!

🚨 STELLAR-303 makes history! First-ever Ph3 trial to show OS benefit of IO in MSS CRC 🎯 Years of grit & belief led us here 🥹 Endless thanks to Exelixis⁩ for the trust & Dr. Hecht for leading this global win with me! 🎉 ⁦@UPMCHillmanCC⁩ ir.exelixis.com/news-releases/…

📢 Press release drop—interpret with appropriate caution. Exelixis reports that zanzalintinib + atezolizumab improved overall survival vs regorafenib in the Phase 3 STELLAR-303 trial for third-line MSS metastatic colorectal cancer. This isn’t the highest bar—survival in this…

So proud of my sister @AnwaarSaeed3 for this historic milestone in tough to treat space. Your relentless dedication, vision and creativity are transforming the future of MSS CRC ✨

Incredible milestone for MSS CRC! 🙌 Congratulations to @AnwaarSaeed3, Dr. Hecht, and the entire STELLAR-303 team on this historic achievement. A huge leap forward for IO in GI oncology. Truly inspiring work! 👏🎯 #CRC #Immunotherapy #STELLAR303 #OncologyInnovation

Our fellows learned so much from the many amazing speakers at the 2025 Pittsburgh Annual Oncology symposium! They're already looking forward to next year! #Hematology #Oncology

🚨 Kicking off the Pittsburgh Annual Oncology Symposium: Experts & Evidence 2025 today! A full day of cutting-edge science, thought-provoking discussions, and collaboration with some of the brightest minds in oncology. @UPMCHillmanCC @UPMCPhysicianEd @PittTweet @JohnRheeMD

Pleased to report FGFR2b expression in gastric cancer and relationship with other biomarkers @ESMO_Open @myESMO. The results of bemarituzumab phase 3 studies are awaited.@OncoAlert @oncodaily sciencedirect.com/science/articl…

Congratulations to @hemeonc_doc Dr. Gaurav Sharma who is completing his heme-onc fellowship this month @USAMitchellCtr! Paper on uncovering IO biomarkers for anal cancers - published today @ESMO_Open sciencedirect.com/science/articl…

🧵 Recently concerns were raised about censoring in CHALLENGE trial, which randomized patients with colon cancer s/p adjuvant chemotherapy to exercise vs education nejm.org/doi/pdf/10.105…

😇 Honored to lead & present topline Ph 2 data for DSP107 +/- Atezolizumab in 3L MSS CRC #ASCO25: 🔹 Median OS: 17 months >> 60% improvement over SOC. 🔹 ~80% with liver metastases—the most challenging subset. 🔜 a randomized Phase 2b trial to advance this promising approach ✨